PCA
RGNX icon

Pallas Capital Advisors’s Regenxbio RGNX Stock Holding History

Pallas Capital Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110K Sell
13,119
-2,426
-16% -$25.5K ﹤0.01% 797
2025
Q4 		$224K Buy
15,545
+385
+3% +$4.8K 0.01% 783
2025
Q3 		$146K Sell
15,160
-2,247
-13% -$19.9K 0.01% 810
2025
Q2 		$143K Buy
17,407
+6,992
+67% +$58.5K 0.01% 780
2025
Q1 		$74.5K Buy
+10,415
New +$77.5K ﹤0.01% 715

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pallas Capital Advisors's RGNX Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Regenxbio (RGNX) stake by 16% in Q1 2026, selling an estimated $25.5K and leaving 13,119 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #797.

Pallas Capital Advisors first reported a position in RGNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $224K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Pallas Capital Advisors held 13,119 shares of Regenxbio worth $110K as of Q1 2026.
  • Pallas Capital Advisors sold 2,426 Regenxbio shares in Q1 2026, an estimated $25.5K.
  • Regenxbio made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #797 holding.
  • Pallas Capital Advisors first reported a position in Regenxbio in Q1 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's Regenxbio position peaked at $224K in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.